Mostrar Notícias:

SGPPrincipaisÚltima HoraBovespa - Brasil

 Ver notícias de outros activos

Pesquisa de notícias relativas à acção SCHERING PLOUGH C (ordenadas pela data):

Reuters

Keytruda sales power Merck to quarterly beat Reuters (Reuters) - Drugmaker Merck & Co (MRK.N) reported better-than-expected first-quarter earnings on Tuesday, helped by a more than 150 percent rise in sales of blockbuster cancer drug Keytruda.

The Pharmaceutical Journal

Hepatitis C: tackling the silent killer The Pharmaceutical Journal 1997: The first alpha interferon, Schering-Plough's Intron A (interferon alpha-2B), is approved for treatment of hepatitis C in the UK. 1999: European blood services begin screening blood with nucleic acid amplification testing (NAT), because it ...

Merck, Schering-Plough set to complete merger Reuters NEW YORK (Reuters) - Merck & Co (MRK.N) and Schering-Plough Corp SGP.N said their $41.1 billion merger will be completed later on Tuesday, marking the close of the second huge deal in the pharmaceutical industry in recent weeks. Pfizer Inc (PFE.

Forbes

Pharma Billionaire Charged With Penny Stock Fraud Forbes Investigators allege an investor named Barry C. Honig served as the ringleader of the scheme. In each of three ... They sold that company, the developer of some of the first sustained release formulations, to Schering-Plough in 1986 for $836 million ... e mais »

Business Wire (press release)

Science Exchange Adds Allergan EVP & Chief R&D Officer David ... Business Wire (press release) PALO ALTO, Calif.--(BUSINESS WIRE)--Science Exchange, Inc. announced today that C. David Nicholson, Ph.D., EVP and Chief R&D Officer at Allergan, has joined the Science Exchange Board of Directors. Dr. Nicholson's experience includes over forty ... e mais »

Philanthropist and animal advocate Thomas J. Sabatino, Jr. joins the ... HSUS News Sabatino is currently Executive Vice President and General Counsel of Aetna, and has previously served in comparable positions at Hertz Global Holdings, Walgreens, United Airlines, Schering-Plough, Baxter International and American Medical International. e mais »

Medscape

Safe Stopping of Tocilizumab in RA: MTX Helps Medscape Second-year data from the SURPRISE rheumatoid arthritis (RA) trial support the finding that many patients who achieve remission can safely stop ? or at least interrupt ? biologic treatment with tocilizumab. Such interruptions might reduce both costs ...

FiercePharma

The top 5 highest-paid women biopharma executives in 2017 FiercePharma ... the Massachusetts Biotechnology Council and recruiting firm Liftstream. The wide gender gap higher up, though improved in recent years, persists: Women only hold a quarter of all C-suite level jobs, and less than 15% joined the board of directors ...

Sleep Disturbances in Elderly Patients: June 2018 Healio Chandra M. Cherukuri, MD, MS; Neeraj Kaplish, MD; Deepthi C. Malepati, MD; Imran S. Khawaja, MBBS, FAASM; Shashi K. Bhatia, MD, FACPsych; and Subhash C. Bhatia, MD, FACPsych ... Inc.; Brandeis University; Bristol Myers Squibb; Clintara, Dianippon ...

Forbes

What You Should Know About Ken Frazier, The CEO Who Just Quit ... Forbes Kenneth C. Frazier, the chairman and chief executive of the U.S. drug maker Merck, resigned from President Donald Trump's American Manufacturing Council on Monday morning, saying in a statement, ?As CEO of Merck and as a matter of personal conscience ... e mais »

Monthly Prescribing Reference

Lonafarnib May Lower Mortality in Hutchinson-Gilford Progeria Monthly Prescribing Reference "Among patients with HGPS, lonafarnib monotherapy, compared with no treatment, was associated with a lower mortality rate after 2.2 years of follow-up," the authors write. "Study interpretation is limited by its observational design." Schering Plough ... e mais »

FiercePharma

Top 10 most productive workforces in biopharma FiercePharma Gilead got its hep C franchise through its 2011 Pharmasset buyout, and as that business declines, Gilead is now looking to grow in the burgeoning CAR-T business with last year's Kite Pharma buy. AbbVie shelled out $20.8 billion for Pharmacyclics and ...

Esperion Announces the Appointment of Jeffrey Berkowitz to Board ... GlobeNewswire (press release) We are confident Jeff will provide important contributions to help us deliver on the promise of bringing our complementary, oral LDL-C lowering therapies to the millions of patients who are inadequately treated with, or unable to gain access to ... e mais »

Merck, Schering-Plough to complete merger Tuesday MarketWatch BOSTON (MarketWatch) -- Merck & Co. MRK, -1.16% and Schering-Plough Corp. SGP, +36.15% said they will complete their $41 billion merger after the market's close on Tuesday. As a result, Schering-Plough's stock will cease trading later Tuesday. e mais »

Merck to Buy Schering-Plough in $41.1 Billion Cash and Stock Deal Seeking Alpha (blog) Not to be outdone by Pfizer (NYSE:PFE) / Wyeth (WYE), Merck (NYSE:MRK) and Schering-Plough (SGP) announced that their Boards of Directors have unanimously approved a merger. Schering has a strong pipeline and was my best of breed to be acquired ...

Merck to buy Schering-Plough for $41.1 billion MarketWatch Before the opening bell Monday, the two major drugmakers said they have agreed to a merger that calls for Schering-Plough SGP, +36.15% shareholders to receive $10.50 in cash and 0.5767 in Merck MRK, -1.16% stock for each share of Schering-Plough.

In Vivo

Bristol/Medarex: A Transformational Acquisition Rooted In ... In Vivo Bristol's $2.4 billion buyout of Medarex in 2009 yielded value equivalent or greater to that realized in larger M&A transactions signed that year, such as Pfizer/Wyeth, Merck/Schering-Plough and Roche/Genentech. The deal made BMS a leader in ...

MedPage Today

Repeat CRP Tests If Spine Disease Uncertain MedPage Today Patients with nonradiographic axial spondyloarthritis (axSpA) who have normal C-reactive protein (CRP) levels at baseline but have high disease activity should have the CRP test repeated after at least 4 weeks to clarify whether they should be eligible ...

TCTMD

SECURE-PCI Comes Up Short for Statin Preloading in ACS Patients TCTMD In PROVE-IT, for example, high-intensity statin therapy started within 7 days of ACS showed a clinical benefit, as did early treatment with ezetimibe (Zetia; Merck/Schering-Plough) in IMPROVE-IT. ?But that still leaves the early window,? she added ... e mais »

Scientists find a way to cure hepatitis C with 6 weeks of treatment EurekAlert (press release) "Given the high cost of sofosbuvir and ledipasvir, and the associated side effects that occur during treatment, we set out to assess whether shortened treatment duration could be an effective option for acute Hepatitis C patients," said Katja Deterding ... e mais »

The Independent

New evidence links 1970s pregnancy test drug to life-changing birth ... The Independent Schering-Plough has now been taken over by Bayer. The company has said the use of Primodos in the 1970s was ?in compliance with prevailing laws?. The pharmaceutical giant maintains the ?evidence for a causal association between the use of hormonal ... e mais »

Forbes (blog)

Should Merck Have Bought Schering-Plough? Forbes (blog) Early this morning, Sanford C. Bernstein analyst Timothy Anderson, a Merck bull, issued a note to investors that asked whether failure for vorapaxar would lead to questions about the Merck-Schering merger. (He refers to the companies by their ... e mais »

CNNMoney.com

Merck and Schering-Plough in $41B merger CNNMoney.com ... and Swiss drugmaker Roche Holding AG continues to pursue a $40 billion hostile bid of Genentech Inc. (DNA). Shares of Merck (MRK, Fortune 500) fell about 11% and Schering-Plough (SGP, Fortune 500) shares were up about 11% in premarket trading. e mais »

Medscape

Cut LDL-C for CV Risk-Reduction, but How Matters: Meta-Analysis Medscape ... P<0.001) and 25% lower risk with intensive diet, bile-acid sequestrants, ileal bypass surgery, or ezetimibe (Zetia, Merck/Schering Plough)?all therapies that help clear cholesterol by upregulating the LDL receptor (RR 0.75, 95% CI 0.66-0.86; P=0.002).

Harvard Business Review

This Pharma Company Stays Innovative by Doing Two Things Harvard Business Review For industries that depend on innovation, sustaining it is a constant challenge. This is particularly the case in biopharmaceuticals, where turning molecules into medicines is notoriously fraught with risk, and failure. When one of us (Vivek) and his ...

Reuters

Schering-Plough to buy Akzo's Organon for $14.4 bln Reuters AMSTERDAM (Reuters) - Schering-Plough Corp SGP.N has agreed to buy Akzo Nobel NV's (AKZO.AS) drugs unit Organon BioSciences for 11 billion euros ($14.4 ... The move gets U.S.-based Schering-Plough a near $5 billion-a-year business in women's health ...

RTE.ie

Animal medicines company purchases Rathdrum site RTE.ie The world's largest manufacturer of animal medicines and vaccines has bought the former MSD pharmaceutical plant in Rathdrum, Co Wicklow. US-based company Zoetis, which already operates two sites in Ireland, confirmed to RTÉ News this evening it has ... e mais »

Franceinfo

Hérouville: le laboratoire pharmaceutique Schering-Plough bientôt ... Franceinfo Depuis 2015, le groupe Merck Sharp & Dohme, propriétaire du laboratoire Schering-Plough, souhaite vendre son site d'Hérouville-Saint-Clair. Un projet a été présenté ce vendredi aux salariés : le groupe français Cenexi est prêt à investir 7 millions d ... e mais »

CNBC

One-on-One with Schering-Plough CEO Fred Hassan CNBC When Hassan took the helm of a struggling Schering-Plough in 2003, he bought back stock as a way to calm the nerves of those who thought the company was headed toward a downward spiral. To reassure analysts and shareholders, Hassan told Cramer ...

Ouest France Entreprises

Près de Caen, Schering-Plough aurait un repreneur Ouest France Entreprises Entreprise de la région. Le groupe pharmaceutique Cenexi reprendrait les 261 salariés et investirait 7 millions d'euros en trois ans. Le projet va être présenté dans quelques jours. Une première annonce a été faite aux salariés vendredi. Hier, c'est la ... e mais »